Shionogi to acquire an additional 11.7% stake in ViiV Healthcare from Pfizer for $2.1bn.

Shionogi, a pharmaceutical company, agreed to acquire an additional 11.7% stake in ViiV Healthcare, a specialist HIV company, from Pfizer, a multinational pharmaceutical and biotechnology corporation, for $2.1bn. “This agreement simplifies ViiV’s shareholder structure and we look forward to continuing our highly successful collaboration with Shionogi to advance ViiV’s pipeline and portfolio of long-acting injectable HIV treatment and prevention medicines. GSK would also like to thank Pfizer for its longstanding partnership in the development of ViiV since its establishment in 2009," David Redfern, ViiV Healthcare Chair.